TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Heart protein clog? new drug aims to clear it and save lives
Disease control OngoingThis study tests an investigational drug called ALXN2220 in about 1181 adults with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM), where abnormal protein builds up in the heart muscle. The drug is designed to remove that protein buildup. The main goal is …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New drug shows promise for rare heart condition in chinese patients
Disease control OngoingThis study tests a drug called eplontersen in Chinese adults with a heart condition caused by a faulty protein (transthyretin amyloid cardiomyopathy). The goal is to see if the drug safely lowers that protein and improves heart health. About 64 participants will receive either ep…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 08:24 UTC
-
Bronx heart database aims to uncover hidden disease in women and minorities
Knowledge-focused OngoingThis study is creating a database of people with a rare, often undiagnosed heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers looked at medical records of 476 patients in the Bronx, a racially and ethnically diverse area, who had a special heart sc…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated May 26, 2026 08:27 UTC